XBiotech (XBIT) Total Non-Current Liabilities (2014 - 2026)
XBiotech (XBIT) posted quarterly Total Non-Current Liabilities of $7.9 million for Q4 2025, down 47.47% year-over-year from $15.1 million in Q4 2024, and up 122.55% quarter-over-quarter from $3.6 million in Q3 2025.
XBiotech (XBIT) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
XBiotech's Total Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $7.9 million for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities fell 47.47% year-over-year to $7.9 million; the TTM figure through Dec 2025 stood at $7.9 million (down 47.47% YoY), while the FY2025 annual figure was $7.9 million, down 47.47% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $7.9 million, up from $3.6 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $17.1 million in Q2 2024, with the low at $2.7 million in Q1 2021.
- The 5-year median for Total Non-Current Liabilities is $4.8 million (2022), against an average of $7.2 million.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities soared 366.67% in 2024, then sank 77.71% in 2025.
- XBiotech's Total Non-Current Liabilities stood at $4.3 million in 2021, then declined by 4.65% to $4.1 million in 2022, then jumped by 47.88% to $6.1 million in 2023, then surged by 147.62% to $15.1 million in 2024, then slumped by 47.47% to $7.9 million in 2025.
- Business Quant data shows XBIT's Total Non-Current Liabilities at $7.9 million in Q4 2025, $3.6 million in Q3 2025, and $3.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | XBiotech | 68.90 Mn | 68.90 Mn | - | 3.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.36 Mn |
| Dec 31, 2025 | 7.93 Mn |
| Sep 30, 2025 | 3.57 Mn |
| Jun 30, 2025 | 3.86 Mn |
| Mar 31, 2025 | 5.41 Mn |
| Dec 31, 2024 | 15.11 Mn |
| Sep 30, 2024 | 15.99 Mn |
| Jun 30, 2024 | 17.14 Mn |
| Mar 31, 2024 | 16.88 Mn |
| Dec 31, 2023 | 6.10 Mn |
| Sep 30, 2023 | 5.29 Mn |
| Jun 30, 2023 | 4.45 Mn |
| Mar 31, 2023 | 3.62 Mn |
| Dec 31, 2022 | 4.13 Mn |
| Sep 30, 2022 | 4.45 Mn |
| Jun 30, 2022 | 9.11 Mn |
| Mar 31, 2022 | 5.24 Mn |
| Dec 31, 2021 | 4.33 Mn |
| Sep 30, 2021 | 3.97 Mn |
| Jun 30, 2021 | 4.00 Mn |